CH Bank Nifty Market Trend for 14-December- 2017

CH: BANK NIFTY TREND -CONSOLIDATE

BANK NIFTY FUTURE LEVELS

SUPP 1: 24850

SUPP 2: 24450

RES 1:25280

RES 2: 25550

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

CH Nifty Market Trend for 14-December- 2017

NIFTY TREND-CONSOLIDATE

NIFTY SPOT LEVELS

SUPP 1: 10135

SUPP 2: 10050

RES 1: 10265

RES 2: 10340

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

CH Stock Market Opening Bell 13-December-2017

Stock Market Opening Bell 13-December-2017

CH CLOSING BELL:

NIFTY FUTURE DOWN 37 @ 10227

BANKNIFTY FUTURE DOWN 129 @ 25048

SENSEX DOWN 148 @ 33079

INR 64.44

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

CH Stock Market Opening Bell 13-December-2017

Opening bell

CH OPENING BELL:

NIFTY FUTURE DOWN 23 @ 10241

BANKNIFTY FUTURE DOWN 65 @ 25113

SENSEX UP 12 @ 33240

INR 64.52

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

International Market Update by Money CapitalHeight

INTERNATIONAL MARKET UPDATE

GOLD $ 1246.40

SILVER $ 15.75

COPPER $ 3.02

CRUDE $ 57.55

INR 64.49

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

World Market Update by Money CapitalHeight

WORLD MARKET UPDATE

HANG SENG 71

NIKKEI -59

SHANGHAI -3

DOWJONES 118.77

NASDAQ -12.76

SGX NIFTY -18

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

CH Bank Nifty Market Trend for 13-December- 2017

BANK NIFTY TREND -BULLISH

BANK NIFTY FUTURE LEVELS

SUPP 1: 24870

SUPP 2: 24685

RES 1:25480

RES 2: 25720

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

CH Nifty Market Trend for 13-December- 2017

NIFTY TREND-BULLISH

NIFTY SPOT LEVELS

SUPP 1: 10185

SUPP 2: 10110

RES 1: 10315

RES 2: 10380

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

GAIL India to Import 5 MT of LNG from the US next fiscal

GAIL IndiaGAIL (India) will import about 5 million tonnes (MT) of LNG from the US next fiscal, replacing the volumes the state-owned utility buys from the spot market. The company has contracted 5.8 MT per annum of liquefied natural gas (LNG) from the US, some of which it has swapped – either by exchanging the gas with someone having it nearer to India or by time-swapping it.

This will improve GAIL India’s margins from next fiscal onwards due to savings from switching from high cost spot LNG to lower cost LNG.

The lower gas prices improve the outlook for all of GAIL’s business divisions: 1) Gas Transmission 2) Gas trading 3) Petchem.

We expect 13% earnings CAGR over FY17-19E EPS on the back of 1) steady volume growth in the core business and 2) stabilization of the petchem units. The stock trades at ~16x FY20E earnings. We have a positive outlook on the stock.

GAIL (India) Ltd is currently trading at Rs492.8, up by Rs11.85 or 2.46% from its previous closing of Rs480.95 on the BSE. The scrip opened at Rs487.9 and has touched a high and low of Rs494.6 and Rs481 respectively.

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

Natco Pharma fixes QIP at Rs937.63 per share

Natco Pharma’s board of directors or committee of directors, may at its discretion, offer a discount of more than 5% on the QIP floor price.

Natco Pharma, a leading domestic player in the oncology, derives ~36% of sales from the oncology business. The company forayed into cardiology and diabetology in 2017. In FY17, the company derived 42% sales from domestic formulations, while international formulations and APIs contributed 40% and 9% respectively to sales in the same period.

The company is focusing on a few high-potential filings predominantly differentiated products through either novel drug delivery systems or complex chemistries. The company plans capex of Rs350cr in FY18. It is likely that the fund raised through QIP will primarily be used to invest in complex generics. Apart from capex, the company requires funds for repayment/prepayment of borrowings, working capital and general corporate purposes.

The details of QIP have not been disclosed by the company. However, in an earlier BSE filing, Natco Pharma had stated that it plans to raise Rs1,500cr through various modes including QIP, Global Depository Receipts (“GDRs”) or American Depository Receipts (“ADRs”) or Foreign Currency Convertible Bonds (“FCCBs”) or fully convertible /partly convertible debentures, etc.

Natco Pharma Ltd is currently trading at Rs974.1, up by Rs13.4 or 1.39% from its previous closing of Rs960.7 on the BSE.

www.capitalheight.com/freetrial.php

Give Missed Call at +91 830-630-830-8

For More Live Updates Visit:

http://moneycapitalheight.blogspot.in/

1 2 3 4 5 740